Skip to main content

Table 2 Univariate Cox model for exploring the association between FT and clinical outcomes in PD before and after weighting

From: Facial tremor in patients with Parkinson’s disease: prevalence, determinants and impacts on disease progression

 

Unweighted sample

Weighted sample

HR (95%CI)

P-value

HR (95%CI)

P-value

Presence of FT at baseline

 Time to death

0.41 (0.22–0.80)

0.006*

0.62 (0.31–1.22)

0.166

 Time to UPDRS-III 11-point increase

0.77 (0.43–1.30)

0.339

0.98 (0.54–1.76)

0.934

 Time to conversion to H&Y stage ≥3

0.98 (0.50–1.78)

0.938

0.66 (0.33–1.30)

0.224

 Time to dyskinesia

0.41 (0.14–0.95)

0.061

0.44 (0.17–1.17)

0.101

 Time to MoCA 3-point decrease

0.93 (0.51–1.61)

0.793

0.67 (0.36–1.23)

0.198

FT as initial symptom

 Time to death

2.82 (1.55–5.11)

< 0.001*

1.75 (0.55–5.54)

0.342

 Time to UPDRS-III 11-point increase

0.97 (0.60–1.55)

0.889

0.74 (0.24–2.31)

0.606

 Time to conversion to H&Y stage ≥3

1.24 (0.69–2.12)

0.467

0.34 (0.08–1.56)

0.167

 Time to dyskinesia

0.51 (0.21–1.27)

0.149

0.81 (0.18–3.70)

0.790

 Time to MoCA 3-point decrease

1.04 (0.63–1.72)

0.885

0.45 (0.13–1.63)

0.226

  1. FT Facial tremor, PD Parkinson’s disease, UPDRS Unified PD Rating Scale, MoCA Montreal Cognitive Assessment
  2. * Significant difference